Navigation Links
Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Date:4/4/2011

iation for Cancer Research (www.aacr.org) being held in Orlando, FL from April 2 through April 6.  That study, entitled "Circulating regulatory T cells (CD4+CD25[high] CD127[low]) decrease in breast cancer patients after vaccination with a modified HER-2/neu HLA class II peptide (AE37) vaccine", will be presented April 5.  The study shows that a subgroup of CD4+ cells that have the potential to suppress immune responses, termed T regulatory cells, actually decrease after immunization with AE37.  This decrease in T regulatory cells was not observed in patients immunized with GP2.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of c
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces $3.0 Million Capital Investment
2. Generex Provides Additional Details for October 21st Live Video Webcast
3. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
4. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
7. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
8. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Techne Corporation Announces Acquisition
11. Life Technologies Announces Launch of 2010 Online Annual Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... a life,sciences company developing revolutionary bench-top flow cytometer systems,today ... financing led by,Fidelity Biosciences and Flagship Ventures. Current investors ...
... 8 Concentric Pharma Advertising, Inc., a,five-year-old ... growing in the,field, has been selected by ... a developmental once-daily,medication for the treatment of ... include a broad range of activities,including branding, ...
... 7 American Oriental,Bioengineering, Inc. (NYSE: AOB ... market conditions and other factors, $85 million aggregate,principal ... qualified,institutional buyers in a private placement exempt from ... as amended (the "Securities,Act")., AOB currently expects ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Concentric Wins Full-Service Professional Assignment From Biopharm Innovator Neuromed 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 3
(Date:4/23/2014)... The trope that the likelihood of an accurate group ... not hold up when a collective faces a variety ... nature. Instead, Princeton University researchers report that smaller groups ... assemblies may become excessively focused on only certain pieces ... to what is known about collective intelligence, or the ...
(Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. ... A potent inhibitor of MMP-2 that acts ... = 1.7 μM). Purity: ≥98% by ... Unstable in solution, reconstitute just prior to ...
MAb to Vasopressin Preservative: NaN3...
Biology Products: